Intellia Therapeutics’ (NTLA) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a research note released on Tuesday morning,Benzinga reports. The firm currently has a $30.00 price target on the stock. Other equities research analysts also recently issued research reports about the company. JPMorgan Chase & Co. reiterated a “neutral” rating […]
HC Wainwright reiterated their buy rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a research note released on Tuesday morning,Benzinga reports. The firm currently has a $30.00 price target on the stock. Other equities research analysts also recently issued research reports about the company. JPMorgan Chase & Co. reiterated a “neutral” rating […]
